Выпусков: 263

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Clinical Pharmacology CME/CNE/CPE Video PVI, PeerView Institute for Medical Education

    • Естественные науки

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Kenneth C. Kalunian, MD / Maureen A. McMahon, MD / Joan T. Merrill, MD - Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient

    Kenneth C. Kalunian, MD / Maureen A. McMahon, MD / Joan T. Merrill, MD - Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient

    Go online to PeerView.com/YHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME video activity, experts in systemic lupus erythematosus (SLE) give a detailed discussion on the autoimmune disease, providing guidance on recognizing the clinical features and confirming a diagnosis, as well as contemporary strategies to manage diverse disease manifestations. Hear what the experts are doing in their clinics. Upon completion of this activity, participants should be better able to: Identify systemic lupus erythematosus (SLE) as a heterogeneous autoimmune disease with a wide range of clinical and serological manifestations that can affect any organ, Employ appropriate criteria to confirm a diagnosis of SLE, recognizing the clinical utility of available classification systems, Utilize evidence-based tools to monitor disease activity in individual SLE patients in daily clinical practice and guide treatment decisions, Describe current treatment options for SLE according to mechanism of action, efficacy, safety, and impact on patient symptoms/quality of life, Develop treatment plans for individual patients with SLE to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage, Effectively communicate and collaborate with SLE patients and other care providers to understand and address the needs of each patient and maximize treatment adherence, quality of life, and survival outcomes.

    • 1 ч. 11 мин.
    • video
    John M. Pagel, MD, PhD - Perspectives on Innovative Treatment for B-Cell Malignancies

    John M. Pagel, MD, PhD - Perspectives on Innovative Treatment for B-Cell Malignancies

    Go online to PeerView.com/BUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss therapeutic innovations in a range of B-cell cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), and how community-based professionals can address the challenges of an increasingly complex B-cell cancer treatment landscape. The panel shares a series of practical insights on the continued validation and emergence of targeted therapy (such as BTK, BCL-2, PI3K, and EZH2 inhibitors) and other innovative options in diseases as diverse as CLL, MCL, FL, and DLBCL. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of targeted therapies and other innovative agents across a range of B-cell cancer settings and patient populations, Cite updated safety and efficacy evidence on novel therapeutics, including single-agent and combination regimens, in patients with cancers such as CLL, FL, MCL, and DLBCL, Select personalized therapy with novel therapeutics for patients with treatment-naïve or relapsed/refractory B-cell cancers, Develop appropriate adverse event management strategies for patients with B-cell cancers who are experiencing toxicity while on therapy with newer therapeutics.

    • 1 ч. 13 мин.
    • video
    Jennifer Wargo, MD, MMSc - Taking the Leap With Immunotherapy in Resectable Melanoma: Immune Checkpoint Inhibitors as Adjuvant and Neoadjuvant Therapy and Other Intersections With Surgical Management

    Jennifer Wargo, MD, MMSc - Taking the Leap With Immunotherapy in Resectable Melanoma: Immune Checkpoint Inhibitors as Adjuvant and Neoadjuvant Therapy and Other Intersections With Surgical Management

    Go online to PeerView.com/NUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in melanoma explore evidence and practical lessons from major studies of adjuvant immunotherapy in melanoma, and provide insights on the future of immune checkpoint blockade in resectable disease. The panel also discusses real-world cases that illustrate how surgeons and oncologists can work together to identify ideal candidates for checkpoint inhibitor therapy and safely integrate immunotherapy into the surgical management of melanoma. Upon completion of this activity, participants should be better able to: Cite current guideline recommendations for the use of adjuvant immunotherapy in resectable melanoma, Summarize updated efficacy findings on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable melanoma, including high-risk stage III disease, Integrate adjuvant immunotherapy into treatment protocols for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.

    • 1 ч. 2 мин.
    • video
    Ken Fujioka, MD - Leveraging the Tools at Hand: Current Perspectives on Weight-Loss Pharmacotherapy for Obesity Management

    Ken Fujioka, MD - Leveraging the Tools at Hand: Current Perspectives on Weight-Loss Pharmacotherapy for Obesity Management

    Go online to PeerView.com/QTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in obesity management discusses aspects of obesity management, including current recommendations, the role of weight-loss pharmacotherapies, evidence regarding current and emerging weight-loss pharmacotherapies, and patient-centered treatment approaches. Upon completion of this activity, participants should be better able to: Summarize current treatment recommendations, with rationale for the long-term use of weight-loss pharmacotherapy in the management of obesity as a chronic disease, Evaluate recent evidence regarding available and emerging weight-loss agents, including current data on efficacy, safety, and anticipated effects in the context of obesity pathophysiology, Incorporate weight-loss pharmacotherapy in personalized obesity management plans, based on disease status and patient characteristics and preferences, Use motivational techniques to engage and support individuals in obesity management.

    • 40 мин.
    • video
    Gayle Jameson, RN, MSN, ACNP-BC, AOCN - Making Headway Toward Better Outcomes in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in an Era of Advances in Care and Research

    Gayle Jameson, RN, MSN, ACNP-BC, AOCN - Making Headway Toward Better Outcomes in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in an Era of Advances in Care and Research

    Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.

    • 1 ч. 10 мин.
    • video
    Marwan Sabbagh, MD, FAAN, CCRI - Exploring Current Guidelines and Emerging Therapeutic Strategies for the Treatment of Dementia-Related Psychosis

    Marwan Sabbagh, MD, FAAN, CCRI - Exploring Current Guidelines and Emerging Therapeutic Strategies for the Treatment of Dementia-Related Psychosis

    Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients’ specific needs and circumstances.

    • 30 мин.

Топ подкастов в категории «Естественные науки»

Слушатели также подписываются на